You are here: Welcome » pharmaceutical_companies » Merck

This is an old revision of the document!


Merck

Merck is a multinational pharmaceutical company based in Kenilworth, New Jersey.1)

Affiliations

World Economic Forum

Merck is a member organization of the World Economic Forum.2)

AcademyHealth

Merck is a contributing member of AcademyHealth.3)

COVID-19

Merck is part of the COVID-19 Therapeutics Accelerator funded by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard to “accelerate treatments, vaccines, and diagnostics”.4)

Ivermectin

Merck is the original patent holder for Ivermectin which has been available for decades and is now off-patent.5) It has proven to be highly effective at preventing and treating COVID-19.6)

Molnupiravir

Merck is producing and marketing an experimental oral mutagenic antiviral pill with Ridgeback Biotherapeutics for COVID-19 called molnupiravir.7) 8) 9)

1)
The Trusted Provider of Medical Information since 1899. Merck Manuals. Retrieved January 18, 2022, from https://archive.ph/nYPYj
2)
Merck. World Economic Forum. Retrieved February 10, 2022, from https://archive.ph/a7J76
3)
Current Organizational Members. AcademyHealth. Retrieved May 8, 2022, from https://archive.ph/CjV83
4)
Moody, M. (2022, January 18). Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine. Merck. https://archive.ph/gpZRy
5)
Speare, R., & Durrheim, D. (2004). Mass treatment with ivermectin: an underutilized public health strategy. Bulletin of the World Health Organization, 82(8), 562.
6)
@CovidAnalysis. (2022, January 17). Ivermectin for COVID-19: real-time analysis of all 91 studies. C19Ivermectin. https://archive.ph/rXrxr
7)
Kilgore, T. (2021, December 3). Merck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pill. MarketWatch. Retrieved December 5, 2021, from https://archive.ph/gLvZG
8)
Moody, M., Ryan, P., Dannenbaum, P., Kruper, R., & Carvalho, C. (2021, October 1). Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck. Retrieved December 5, 2021, from https://archive.ph/Ov4Cg
9)
Halford, B., Howes, L., & Satyanarayana, M. (2021, October 1). Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19. Chemical & Engineering News; American Chemical Society. https://archive.ph/8sJfE
Back to top